Structure via PubChem · Public domain (PubChem)
elafibranor
Sign in to saveElafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis.
Chemical data
- Formula
- C22H24O4S
- Molecular weight
- 384.5 g/mol
- IUPAC name
- 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid
- SMILES
- CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC
- InChIKey
- AFLFKFHDSCQHOL-IZZDOVSWSA-N
- XLogP
- 5.1
- Polar surface area
- 88.9 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2024
- Admin. routes
- oral
- Indications
- non-alcoholic fatty liver disease, primary biliary cirrhosis, liver disease, non-alcoholic fatty liver
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 384.14
Show 4 more facts
- medical condition treated
- primary biliary cholangitis
- chemical formula
- C₂₂H₂₄O₄S
- canonical SMILES
- CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)C=CC(=O)C2=CC=C(C=C2)SC
- isomeric SMILES
- CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC
via Wikidata · CC0
~3 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- History
- Society and culture
- Legal status
- Names
- Research
- References
Elafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis.
Elafibranor is a dual PPARα/δ agonist. Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro.
Excerpted from Wikipedia’s “elafibranor” article, available under the CC BY-SA 4.0 licence.